FDA Approves New Prostate Cancer Treatment From AstraZeneca and Merck

Members of a large subset of prostate cancer patients with tumors that have already spread have a new chemotherapy-free treatment option. The FDA on Wednesday approved Lynparza, a PARP inhibitor from AstraZeneca (NYSE:AZN) and Merck (NYSE:MRK) that previously had been approved to treat people with ovarian and breast cancers.